Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Equity Ratio (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Equity Ratio for 13 consecutive years, with 0.48 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 33.89% to 0.48 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.48, a 33.89% decrease, with the full-year FY2025 number at 0.48, down 33.89% from a year prior.
  • Equity Ratio was 0.48 for Q4 2025 at Madrigal Pharmaceuticals, up from 0.46 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.84 in Q1 2021 to a low of 0.07 in Q3 2022.
  • A 5-year average of 0.58 and a median of 0.67 in 2022 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: plummeted 91.28% in 2022, then surged 674.46% in 2024.
  • Madrigal Pharmaceuticals' Equity Ratio stood at 0.72 in 2021, then decreased by 24.12% to 0.54 in 2022, then grew by 16.23% to 0.63 in 2023, then rose by 14.38% to 0.72 in 2024, then plummeted by 33.89% to 0.48 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Equity Ratio are 0.48 (Q4 2025), 0.46 (Q3 2025), and 0.69 (Q2 2025).